Shan Fu

Abstract Patients progressing after CD19-targeted immunotherapy in r/r B-ALL experience poor outcomes. CD22-targeted therapies, including CD22 CAR-T cells and Inotuzumab Ozogamicin, show promise as alternatives, although data in those patients is limited. This study retrospectively analyzed 43 r/r B-ALL patients who had previously received CD19-targeted therapy at two centers in China. Among these patients, 27.9% received blinatumomab, 58.1% received CD19 CAR-T cells, and 14% received both.

Discussion This study presents updated efficacy and safety results from 141 patients with R/RMM who underwent BCMA CAR-T cell therapy at our center. The findings are consistent with previously published clinical trial data.13 17 19 20 The median OS for these patients with advanced R/RMM has not yet been reached and is projected to exceed 60 months. Notably, among the 60 patients who demonstrated ongoing responses, 13 have maintained long-term responses for over 4 years.